Rivaroxaban-fig11.jpg (Rivaroxaban Fig11)
Rivaroxaban Tablet
Product Images NDC 42571-345
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 42571-345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Rivaroxaban-fig12.jpg (Rivaroxaban Fig12)
Rivaroxaban-fig2.jpg (Rivaroxaban Fig2)
Rivaroxaban-fig3.jpg (Rivaroxaban Fig3)
This text mentions interacting drugs and provides information about the effects of combined P-gp inhibitors, strong/moderate CYP3A inhibitors, and a strong CYP1A inducer on pharmacokinetics (PK). It appears to be discussing potential drug interactions and their impact on drug metabolism and efficacy.*
Rivaroxaban-fig9.jpg (Rivaroxaban Fig9)
Rivaroxaban-labla.jpg (Rivaroxaban Labla)
The text provides information about a medication in tablet form called Rivaroxaban. Each tablet contains 2.5 grams of the active ingredient. The usual dosage instructions can be found in the package insert for full prescribing information. The tablets should be stored at a temperature range of 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). It is important to keep the medication out of reach of children. The product is labeled with NDC code 42571-345-30 and has been manufactured by Micro Labs Limited in Goa, India, and by Micro Labs USA, Inc. in Somerset, NJ. The packaging contains 30 tablets.*
Rivaroxaban-str-1.jpg (Rivaroxaban Str 1)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
